Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 1, 2007, Pages

  Giannico, Giovanna ^a   Cortes, Pedro ^a   Baccora, Mohammed H ^a   Hassett, Clare ^a   Taube, David W ^a   Yee, Jerry ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Diabetic nephropathy; Matrix catabolism; Mesangial cells; Plasminogen inhibitor type 1; Sulfonylureas; endosulfine

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GLIBENCLAMIDE; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

EID: 33846244681     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00210.2006     Document Type: Article

References (52)

1. Ardaillou N, Bellon G, Nivez MP, Rakotoarison S, Ardaillou R. Quantification of collagen synthesis by cultured human glomerular cells. Biochim Biophys Acta 991: 445-452, 1989.
2. Asano K, Cortes P, Garvin JL, Riser BL, Rodríguez-Barbero A, Szamosfalvi B, Yee Y. Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney Int 55: 2289-2298, 1999.
3. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039-1049, 1995.
4. Biederman JI, Yee J, Cortes P. Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis. Kidney Int 66: 2308-2314, 2004.
5. Biederman JI, Vera E, Pankhaniya R, Hassett C, Giannico G, Yee J, Cortes P. Effects of sulfonylureas, α-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes. Kidney Int 67: 554-565, 2005.
6. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN. Glycated albumin stimulates TGF-β1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 59: 673-681, 2001.
7. Chutkow WA, Simon MC, Le Beau MM, Burant CF. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 45: 1439-1445, 1996.
8. 3H1 myocytes. Diabetes 39: 1399-1407, 1990.
9. Cortes P, Riser BL, Asano K, Rodríguez-Barbero A, Narins RG, Yee J. Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney Int 54: 1985-1998, 1998.
10. Cortes P, Yee J, Taube DW, Hasset C, Sitkins J. Alpha-endosulfine enhances collagen formation in mesangial cells (MC) exposed to high glucose (HG) concentration (Abstract). J Am Soc Nephrol 16: 405A, 2005.
11. Del Valle-Pérez B, Marínez-Estrada O, Vilaró S, Ventura F, Viñals F. cAMP inhibits TGF-β1-induced in vitro angiogenesis. FEBS Lett 569: 105-111, 2004.
12. Du Z, Ferguson W, Wang T. Role of PKC and calcium in modulation of effects of angiotensin II on sodium transport in proximal tubule. Am J Physiol Renal Physiol 284: F688-F692, 2003.
13. + channels: generating excitement in pancreatic β-cells. Diabetes 45: 845-853, 1996.
14. Dulubova I, Horiuchi A, Snyder GL, Girault JA, Czernik AJ, Shao L, Ramabhadran R, Greengard P, Nairn AC. ARPP-16/ARPP-19: a highly conserved family of cAMP-regulated phosphoproteins. J Neurochem 77: 229-238, 2001.
15. Eckel J. Direct effects of glimepiride on protein expression of cardiac glucose transporters. Hormone Met Res 28: 508-511, 1996.
16. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220, 2002.
17. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Ann Rev Pharmacol Toxicol 33: 597-637, 1993.
18. Fioretto P, Steffes MW, Sutherland DER, Mauer M. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. Kidney Int 48: 1929-1935, 1995.
19. 1(IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol Renal Fluid Electrolyte Physiol 267: F632-F638, 1994.
20. Geng X, Li L, Watkins S, Robbins PD, Drain P. The insulin secretory granule is the major site of KATP channels of the endocrine pancreas. Diabetes 52: 767-776, 2003.
21. Hagiwara H, Kaizu K, Uriu K, Noguchi T, Takagi I, Qie YL, Seki T, Ariga T. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb Res 111: 301-309, 2003.
22. Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflügers Arch 408: 615-618, 1977.
23. Heaton JH, Dlakic WM, Gelehrter TD. Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost 89: 959-966, 2003.
24. Heilig CW, Concepcion LA, Riser BL, Freytag SO S, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96: 1802-1814, 1995.
25. Heron L, Virsolvy A, Apiou F, Le Cam A, Bataille D. Isolation, characterization, and chromosomal localization of the human ENSA gene that encodes alpha-endosulfine, a regulator of beta-cell K(ATP) channels. Diabetes 48: 1873-1876, 1999.
26. Hornbeck P, Winston SE, Fuller Chapter 11 SA. Enzyme-linked immunosorbent assay (ELISA). In: Current Protocols in Molecular Biology, edited by Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K. New York: Greene Publishing Associates and Wiley-Interscience, 2005, p. 11.2.8 -11.2.10.
27. Ingelfinger JR. Forestalling fibrosis. New Engl J Med 349: 225-226, 2003.
28. Jennings PE, Belch JJF. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 49: 23-26, 2000.
29. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 69: 1547-1555, 2005.
30. Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. J Lab Clin Med 144: 69-77, 2004.
31. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med 138: 59-68, 2002.
32. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-β1-induced kidney disease. Kidney Int 68: 2651-2666, 2005.
33. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 67: 1762-1771, 2005.
34. Lee HS, Moon KC, Song CY, Kim BC, Wang S, Hong HK. Glycated albumin activates PAI-1 transcription through Smad DNA binding sites in mesangial cells. Am J Physiol Renal Physiol 287: F665-F672, 2004.
35. Muller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42: 1852-1867, 1993.
36. Nicholas SB, Aguiniga E, Ren Y, Kim J, Joyce W, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh W. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67: 1297-1307, 2005.
37. Noda Y, Mori A, Cossins E, Packer L. Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study. Metabolism 49: 14-16, 2000.
38. Ohyama K, Seyer JM, Raghow R, Kang AH. Extracellular matrix phenotype of rat mesangial cells. J Lab Clin Med 116: 219-227, 1990.
39. Onozato ML, Tojo A, Goto A, Fujita T. Radical scavenging effect of glicazide in diabetic rats fed with high cholesterol diet. Kidney Int 65: 951-960, 2004.
40. Peyrollier K, Heron L, Virsolvy-Vergine A, LeCam A, Bataille D. Alpha endosulfine is a novel molecule, structurally related to a family of phosphoproteins. Biochem Biophys Res Commun 223: 583-586, 1996.
41. Prendegast BD. Glyburide and glipizide, second generation oral sulfonylurea hypoglycemic agents. Clin Pharm 3: 473-485, 1984.
42. Scivittaro V, Ganz MB, Weiss MF. AGE induce oxidative stress and activate protein kinase C-βII in neonatal mesangial cells. Am J Physiol Renal Physiol 278: F676-F683, 2000.
43. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 70: 361-372, 1981.
44. Song CY, Kim BC, Hong HK, Lee HS. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-β signaling in mesangial cells. Kidney Int 67: 1743-1752, 2005.
45. Steffes MW, Østerby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081, 1989.
46. + channels in mitochondria. Biochem Biophys Res Commun 241: 693-697, 1997.
47. ATP channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 109: 509-516, 2002.
48. + channel. Kidney Int 61: 1739-1749, 2002.
49. Takla PG. Glibenclamide. Anal Profile Drug Subs 10: 337-355, 1981.
50. + channels contribute to local metabolic coronary vasodilation in experimental diabetes. Diabetes 51: 1201-1207, 2002.
51. Wang S, Hirschberg R. Bone morphogenic protein-7 signals opposing transforming growth factor β in mesangial cells. J Biol Chem 279: 23200-23206, 2004.
52. Yee J, Cortes P, Barnes JL, Alviani R, Biederman JI, Szamosfalvi B. Rat mesangial α-endosulfine. Kidney Int 65: 1731-1739, 2004.